Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01993888 · ClinicalTrials.gov registry record · Phase 3
The EVARREST® Fibrin Sealant Patch Liver Study
A Phase 3 study, sponsored by Ethicon.
- Completed
- Registry status
- Phase 3
- Development phase
- 102
- Enrollment target
NCT01993888: Completed Phase 3 study, sponsored by Ethicon.
NCT01993888 is a Phase 3 study that has completed, run by Ethicon. The registered enrollment target is 102 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (87% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01993888, a Phase 3 study, has completed, sponsored by Ethicon.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 102 participants
- Enrollment target
Study Summary
To evaluate the safety and hemostatic effectiveness of EVARREST® Fibrin Sealant Patch (EVARREST) versus standard of care treatment (SoC) in controlling parenchymal bleeding during hepatic surgery.
Primary Outcome
Proportion of subjects achieving hemostasis at the TBS at 4-minutes following randomization and with no re-bleeding requiring treatment at the TBS any time prior to initiation of wound closure. Hemostasis is defined as no detectable bleeding at the TBS.
Interventions
- BIOLOGICAL EVARREST® Fibrin Sealant Patch
- OTHER Standard of Care (SoC)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 102 participants |
| Start Date | 2013-10 |
| Est. Completion | 2014-09 |
| Phase | Phase 3 |
What the finished NCT01993888 record still lists
NCT01993888 is an interventional study that assigns participants to a tested intervention. The registered 102 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (87% lower).
The record links to 0 conditions, and to 2 interventions - of which EVARREST® Fibrin Sealant Patch is the first listed.
NCT01993888 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01993888 about?
NCT01993888 is a clinical study titled "The EVARREST® Fibrin Sealant Patch Liver Study". To evaluate the safety and hemostatic effectiveness of EVARREST® Fibrin Sealant Patch (EVARREST) versus standard of care treatment (SoC) in controlling parenchymal bleeding during hepatic surgery.
What is the current status of trial NCT01993888?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 102 participants. The study started on 2013-10. Estimated completion is 2014-09.
What interventions are being tested in trial NCT01993888?
The interventions under investigation include: EVARREST® Fibrin Sealant Patch (BIOLOGICAL), Standard of Care (SoC) (OTHER).
Who is sponsoring clinical trial NCT01993888?
This trial is sponsored by Ethicon, which has 38 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01993888's enrollment target sits among peer trials
102 1676th of 2000 higher than 321 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03704662 · 102 participants · NA
Preoperative Fractionated Radiation Therapy Versus Stereotactic Body Radiation Therapy for Resectable or Borderline Resectable, or Locally Advanced Type A Pancreatic Adenocarcinoma
- NCT04174742 · 102 participants
Self Reported Pain in Women While Undergoing Treatment for Non-metastatic Breast Cancer
- NCT04275362 · 102 participants
Gait Analysis of a Lateral-Pivot Design Total Knee Replacement
- NCT04541082 · 102 participants · Phase 1
Phase I Study of Oral ONC206 in Recurrent and Rare Primary Central Nervous System Neoplasms
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia